Efficacy and challenges involving combination therapies in CLL

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chronic lymphocytic leukemia (CLL) is a mature monoclonal B lymphocyte expansion.
• CLL affects secondary lymphocytic organs, blood, and bone marrow.
• Understanding CLL pathophysiology is crucial for effective treatment.

Purpose of the Study:

• To provide an in-depth review of CLL.
• To emphasize pathophysiology, cytogenic changes, and treatment strategies.
• To explore the efficacy and challenges of novel therapies.

Main Methods:

• Literature review of CLL pathophysiology.
• Analysis of cytogenic changes in CLL.
• Evaluation of Bruton tyrosine kinase (BTK), B cell lymphoma 2 (BCL2), and phosphatidylinositol 3-kinase (PI3K) inhibitors.
• Comparison of monotherapy and combination therapy efficacy.

Main Results:

• Novel therapies like BTK, BCL2, and PI3K inhibitors show promise but face challenges.
• Treatment efficacy varies based on patient response.
• Understanding resistance mechanisms is key to managing chemoresistance and intolerance.

Conclusions:

• Innovative strategies are needed to overcome treatment resistance in CLL.
• Optimizing treatment regimens can enhance patient outcomes.
• Further research is required to fully elucidate the role of novel agents in CLL management.